Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others


Craig Leonardi, MD
Central Dermatology
St. Louis, Missouri, United States
IPC President Elect/Vice President

Dr. Leonardi is clinical professor of dermatology at St. Louis University School of Medicine in St. Louis, Mo., where he also has a private practice. He received his medical degree from the University of Miami School of Medicine in Florida, and completed an internship in pediatrics and residency in dermatology at the University of Miami/Jackson Memorial Hospital. Dr. Leonardi is certified by the American Board of Dermatology. He is a fellow of the American Academy of Dermatology and a member of the Noah Worcester Dermatological Society. He is a past member of the medical board of the National Psoriasis Foundation. Dr. Leonardi has extensive experience using new biologics in the treatment of psoriasis. He has been a speaker at national, regional and state venues, and serves on the advisory boards of several pharmaceutical companies. He has been involved in more than 150 clinical trials and has published more than 150 original articles and abstracts.

Last Updated: May 08, 2012

LluĂ­s Puig, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
IPC Board Member

Prof. Lluís Puig is Director of the Dermatology Department at Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona and Prof. of Dermatology at Autonomous University of Barcelona (UAB) Medical School. Prof. Puig received a medical degree (Hon) at the Medical Faculty of UAB and was a recipient of the Special Curricular Award upon graduating in 1982. In 1987 he completed his residency training in Dermatology at HSCSP Department of Dermatology and received the Spanish Board Certificate in Medical-Surgical Dermatology and Venereology. In 1991 he completed his PhD on pharmacologic modulation of lipid inflammatory mediators in psoriasis at UAB, and was recipient to the Special Award for doctoral theses during that year. Prof. Puig worked as a Senior Research Associate at the Institute of Biomedical Research. His body of work includes nine research projects, on a wide variety of subjects related to the pathophysiology of psoriasis, experimental pharmacology and inmunohistopathology, among others. Over the past ten years, Prof. Puig has focused his clinical research on treatment of psoriasis with biological agents and has participated in 21 clinical trials to date. The results of his research have been presented at both national and international meetings, have been the subject of more than 250 papers, including review articles and continuous medical education papers, and 10 international book chapters. Prof. Puig is an Editorial Board Member of Piel, Actas Dermosifiliogrficas, Medicina Cutnea Latinoamericana, Medicina Clnica, among other journals. He served as a reviewer for a wide number of scientific publications including the Archives of Dermatology, the British Journal of Dermatology and the Journal of the European Academy of Dermatology and is a founding member of several working groups of the Spanish Academy of Dermatology and Venereology. He is a member of the EADV, AAD, ESDR, ASDP, ISDP, GRAPPA, and other societies. He is a board member of the International Psoriasis Council.

Last Updated: Jan 26, 2018


Richard Warren, BSc, MBChB, MRCP, PhD
University of Manchester, Salford Royal Foundation Hospital
Salford, England, United Kingdom

Richard Warren is a Clinical Senior Lecturer and Honorary Consultant Dermatologist in Manchester, UK. He graduated from Liverpool University with a first class honours degree in Pharmacology and gained his Medical degree, with honours, one year later. His work in Dermatology has focussed on pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility of psoriasis and more recently biological therapies and their use in psoriasis. For his work into the pharmacogenetics of methotrexate he has received national and international awards.

Last Updated: May 08, 2012

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.